JHJohan Hansson

Johan Hansson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Johan Hansson has a total of 229 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)

    by Ylva Naeser, Hildur Helgadottir, Johan Hansson, Christian Ingvar, Nils O. Elander, Petra Flygare, Cecilia Nilsson, Frida Jakobsson, Antonios Valachis, Dimitrios Papantoniou, et al.

    The benefit of imaging in the follow-up setting for high-risk melanoma patients is uncertain, and even less is known about the impact of intensive follow-up on the patient´s quality of life. In 2017, a Swedish prospective randomized multicenter study started, in which high-risk melanoma patients are randomly assigned 1:1 to follow-up by physical examinations +/− whole-body imaging. The first-year examinations are scheduled at 0, 6 and 12 months. The aim of this study was to investigate whether the patients´ health-related quality of life (HRQoL) and levels of anxiety and depression were affected at 1 year by imaging. Anxiety/depression and HRQoL were assessed at 0 and 12 months by the questionnaires Hospital Anxiety and Depression (HAD) scale and EORTC QLQ-C30 version 3. Expected baseline QLQ-C30 values for the patients were calculated using data from the general population. In total, 204 patients were analyzed. Mean differences in subscale scores at 1 year were not statistically significant either for HRQoL or for anxiety/depression. Baseline HRQoL did not differ from expected values in the general Swedish population. In conclusion, the patients in general coped well with the situation, and adding whole-body imaging to physical examinations did not affect the melanoma patients’ HRQoL or levels of anxiety or depression.


  • Open Access

    PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

    by Linda Vidarsdottir, Alireza Azimi, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, et al.

    Approximately 50% of human cutaneous melanomas carry activating mutations in the serine/threonine protein kinase BRAF. BRAF inhibitors (BRAFi) selectively target the oncogenic BRAF V600E/K and are effective in approximately 80% of patients carrying the mutation. However, resistance to BRAFi is common and emerges within a median time of 6-7 months of treatment and is prolonged to 11 months when combined with MEK inhibitors. Better characterization of the underlying molecular processes is therefore needed to further improve treatments. Inactivation of the tumor suppressor gene PTEN has been suggested to occur during melanomagenesis and drug resistance development. We recently demonstrated that transcription of PTEN is negatively regulated by an antisense RNA from the PTEN pseudogene (PTENP1-AS) and here set out to investigate the impact of this molecular pathway on the resistance to BRAFi and clinical outcome. We used a panel of BRAFi resistant A375 sublines, and observed increased levels of PTENP1-AS associated with reduced expression of PTEN . Furthermore, this loss of PTEN expression was correlated to increased recruitment of Enhancer of zeste homolog 2 (EZH2) and formation of the transcriptional repression mark H3K27me3 at the PTEN promoter in the resistant cells. We demonstrated that targeting of PTENP1-AS was able to re-activate the expression of PTEN and sensitize resistant melanoma cells to BRAFi. Finally, we showed that PTENP1-AS is a promising prognostic marker for clinical outcome in melanoma patients as high expression of PTENP1-AS in regional lymph node metastases from stage III melanoma patients correlated with poor survival.

  • Top Cited Papers
    Open Access

    Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

    by N. Basset-Séguin, A. Hauschild, R. Kunstfeld, J. Grob, B. Dréno, L. Mortier, P.A. Ascierto, L. Licitra, C. Dutriaux, L. Thomas, et al.


  • Open Access

    Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

    by Johan Falkenius, Hemming Johansson, Rainer Tuominen, Marianne Frostvik Stolt, Johan Hansson, Suzanne Egyhazi Brage

    The variable prognosis in stage III cutaneous melanoma is partially due to unknown prognostic factors. Improved prognostic tools are required to define patients with an increased risk of developing metastatic disease who might benefit from adjuvant therapies. The aim was to examine if cellular immune markers in association with tumor proliferation rate and BRAF mutation status have an impact on prognosis in stage III melanoma. We have used two sets of case series with stage III disease: 23 patients with short survival (≤ 13 months) and 19 patients with long survival (≥ 60 months). Lymph node metastases were analyzed for Ki67, CD8 and FOXP3 protein expression using immunohistochemistry. BRAF mutation status was analyzed in a previous study on the same samples. Low tumor proliferation rate was significantly associated with a better prognosis (p = 0.013). Presence of FOXP3+ T cells was not correlated to adverse clinical outcome. A highly significant trend for a longer survival was found in the presence of an increasing number of markers; CD8+ and FOXP3+ T cells, low tumor proliferation and BRAF wildtype status (p = 0.003). Presence of at least three of these four markers was found to be an independent favorable prognostic factor (OR 19.4, 95% CI 1.9-197, p = 0.012), when adjusting for ulceration and number of lymph node metastases. Proliferation alone remained significant in multivariate analyses (OR 26.1, 95% CI 2.0-344, p = 0.013) but with a wider confidence interval. This panel still remained independent when also adjusting for a previously identified prognostic glycolytic-pigment panel. We have demonstrated that presence of immune cells in association with tumor proliferation and BRAF mutation status may further contribute to identify stage III melanoma patients with high risk of relapse.


    • 9 May 2017
      • Vol. 114

    [Great advances in the systemic treatment in malignant melanoma patients].

    by Gustav Ullenhag, Johan Hansson, Lars Ny

    Great advances in the systemic treatment in malignant melanoma patients Up until a few years ago there was no systemic treatment with the capacity to prolong overall survival for patients with advanced malignant melanoma. Several new treatments have been established in clinical practice in recent years and they belong to two main groups; checkpoint inhibitors and inhibitors of an intracellular pathway (MAP kinase). The latter drugs are only active in melanomas with an activating BRAF mutation, which is present in half of the patients. Side effect management is important and in particular for the checkpoint inhibitors, which activate the immune system and frequently provoke immune related reactions. The introduction of these new treatments has substantially improved prognosis and some patients might even be cured. Based on ongoing research, more therapeutic breakthroughs can be anticipated in the years to come.

  • Epidemiology of cutaneous melanoma in Sweden—Stage‐specific survival and rate of recurrence

    by Julia Rockberg, Justyna M. Amelio, Aliki Taylor, Leif Jörgensen, Peter Ragnhammar, Johan Hansson

    Cutaneous malignant melanoma (CMM) incidence is increasing globally, making a thorough understanding of the disease and its outcomes essential for optimizing care even more urgent. In this population‐based, retrospective study, we investigated stage‐specific survival and recurrence/progression rates of CMM among patients diagnosed in Stockholm County Council during 2005–2012, before the wide introduction of targeted therapy. A total of 3,554 CMM patients from the Stockholm Melanoma Register were included. Information on comorbidities, progression, death, and treatments was obtained from nationwide registers and hospital electronic medical records. Unadjusted 5‐year survival varied from 91.4% for stage I to 24.6% for stage IV patients. Stage, age and gender were predictors of survival, with gender an independent predictor of survival for stages IA and IIA. 74.6% of patients remained recurrence/progression‐free during follow‐up, with 5‐year recurrence/progression‐free survival rates varying from 85.3% to 12.9% among stages I and IV patients, respectively. In addition to stage, male gender, and age, circulatory system comorbidities increased the risk for recurrence/progression. No statistically significant differences in progression rate for operated and non‐operated patients could be detected, possibly due to high rate (98.9%) of surgery. Our estimates of survival and recurrence rates are consistent with historical and global expectations and can serve as a baseline to gauge population‐level improvements with use of novel melanoma treatments.


  • Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma (CMM).

    by Hanna Eriksson, Warangkana Lohcharoenkal, Fernanda Costa-Svedman, Eniko Sonkoly, Suzanne Egyhazi Brage, Johan Hansson, Andor Pivarcsi

    9579 Background: MicroRNAs (miRs) are short, non-coding RNAs that regulate gene expression at the post-transcriptional level. Exosomes are nanometer sized extracellular vesicles secreted by all types of cells and found in body fluids. MiRs are carried within exosomes as intercellular communication vesicles. MAP-kinase inhibitors (MAPKi) are widely used to treat patients with incurable CMMs harboring BRAFV600 mutations, inducing rapid tumor responses but limited durable benefit due to the emergence of resistance. Our aim was to identify possible predictive biomarkers of treatment response to MAPKi in stage IV CMM. Methods: Plasma samples were obtained before and during therapy with MAPKi. Clinical data for each patient was collected. Exosomes were isolated from plasma, RNA was extracted and used for miRNA expression profiling using Exiqon PCR Array. Differential expression of the identified miRNAs in repeated sampling was correlated with therapy response and PFS. Results: After data filtering and normalization, an average of 135 miRs were detectable in the circulation from 14 CMM patients treated with MAPKi. Through pair-wise comparison 14 miRs were identified to be differentially expressed between the pre-therapy (PT) and during therapy (DT) samples (p < 0.05). The extent of changes in miR-191-5p levels correlated with PFS and could have predictive value (Cox regression model). Patients with low expression of miR-191-5 PT had longer PFS (HR = 0.21; 95% CI = 0.046 - 0.95; p = 0.042) compared to patients with high expression PT. The median survival was 205.0 vs. 98.0 days in the low vs. high miR-191-5 PT patient groups, respectively. A low miR-191-5 DT/PT ratio was associated with longer PFS (HR = 0.23; 95% CI = 0.060 - 0.89; p = 0.0332). The median survival was 234.5 vs. 121 days in the low vs. high miR-191-5 DT/PT ratio patient groups, respectively. Conclusions: MiR-191-5p may be a possible candidate as predictive biomarker for treatment outcome in stage IV CMM patients receiving MAPKi therapy.

  • Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).

    by Johan Hansson, Axel Hauschild, Rainer Kunstfeld, Jean Jacques Grob, Brigitte Dréno, Laurent Mortier, Paolo Antonio Ascierto, Lisa F. Licitra, Caroline Dutriaux, Luc Thomas, et al.

    9532 Background: VISMO, a first-in-class HPI, is approved (US and EU) for use in adults with aBCC. STEVIE is an open-label study focusing on safety of VISMO in pts with aBCC in a real-world setting. We present data from the primary analysis. Methods: Adult pts (laBCC, mBCC) received oral VISMO 150 mg QD until progressive disease, unacceptable toxicity, or withdrawal. Primary objective is safety; pts are followed for 12 months after last dose of VISMO. Secondary objectives include efficacy and quality of life. Results: This analysis includes 1215 pts (laBCC, n = 1119; mBCC, n = 96) at 165 sites in 36 countries. Median (range) age was 72.0 (18.0-101.0) yrs. At the time of analysis, 375 (31%) patients remained on study. Median (range) treatment duration was 8.6 (0-44) months. Treatment-emergent AEs (TEAEs) included muscle spasm (66.4%), alopecia (61.5%), dysgeusia (54.6%), decreased weight (40.6%), decreased appetite (24.9%), asthenia (24.0%), nausea (17.9%), and ageusia (17.5%). Serious TEAEs occurred in 289 pts (23.8%). There was no trend of increased TEAEs or grade ≥ 3 TEAEs with increased time on treatment adjusted by pt-yr. Forty-six pts died from grade 5 TEAEs. Seven deaths were considered by investigator (INV) to be related to VISMO (2 myocardial infarction, 1 each of cardiorespiratory arrest, pancreatitis, pulmonary embolism, ischemic stroke, renal failure; all involved confounding factors). Best overall response (RECIST 1.1; INV-assessed) in pts with histologically confirmed measurable baseline disease (laBCC, n = 1077; mBCC, n = 84) included complete response (CR) (33.4% laBCC; 4.8% mBCC) and partial response (35.1% laBCC; 32.1% mBCC). Median duration of response was 23.0 (95% confidence interval [CI]: 20.4, 26.7) and 13.9 (95% CI: 9.23, not estimable) months in pts with laBCC and mBCC, respectively. Median progression-free survival was 23.2 (95% CI: 21.4, 26.0) and 13.1 (95% CI: 12.0, 17.7) months in pts with laBCC and mBCC, respectively. Conclusions: The primary analysis of STEVIE, the largest ever clinical trial in pts with aBCC, confirms the previously observed safety profile and high response rates with VISMO, including many CRs as well as durable responses. Clinical trial information: NCT01367665.


  • Open Access

    Erratum to: Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial

    by Roger Olofsson Bagge, Lars Ny, Charlotta All-Ericsson, Malin Sternby Eilard, Magnus Rizell, Christian Cahlin, Ulrika Stierner, Ulf Lönn, Johan Hansson, Ingrid Ljuslinder, et al.

  • Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

    by Nicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Laurent Mortier, Paolo A Ascierto, Lisa Licitra, Caroline Dutriaux, Luc Thomas, et al.